Publications & Presentations

Proven in Scientific Publications & Presentations

Below are links to scientific publications and presentations related to the efficacy of NeuroStar Advanced Therapy:

 

(links in bold to link outside the site, and require “You are leaving” box similar to current site)

You are leaving a Neuronetics website.

This link provides you with access to recent published information and news about NeuroStar® Advanced Therapy and new options for the treatment of depression. Neuronetics does not provide any assurances of the accuracy of this information and may not agree with the opinions of the authors.

Click here to continue.

 

NeuroStar® Advanced Therapy is indicated for the treatment of major depressive disorder in adult patients who have failed to receive satisfactory improvement from prior antidepressant medications in their current episode. NeuroStar® Advanced Therapy noninvasively stimulates the left prefrontal cortex of the brain to treat the symptoms of major depression. It requires 4 to 6 weeks of treatment. For full safety and prescribing information, click here.

Avery DH, et al. (2008). Transcranial Magnetic Stimulation in the Acute Treatment of Major Depressive Disorder: Clinical Response in an Open-Label Extension Trial. J Clin Psychiatry, 69(3): 441-451. www.ncbi.nlm.nih.gov/pubmed/18294022

Carpenter, LL, et al. (2021). Comparison of Clinical Outcomes with Two Transcranial Magnetic Stimulation Treatment Protocols for Major Depressive Disorder. Brain Stim, 14(1): 173-180. https://pubmed.ncbi.nlm.nih.gov/33346068/

Carpenter LL, et al. (2012). Transcranial Magnetic Stimulation (TMS) for Major Depression: A Multisite, Naturalistic, Observational Study of Acute Treatment Outcomes in Clinical Practice. Depression and Anxiety, 29(7):587-596. www.ncbi.nlm.nih.gov/pubmed/22689344

Demitrack MA, et al. (2009). Clinical Significance of Transcranial Magnetic Stimulation (TMS) in the Treatment of Pharmacoresistant Depression: Synthesis of Recent Data. Psychopharmacol Bulletin, 42(2):5-38. www.ncbi.nlm.nih.gov/pubmed/19629020

Dunner DL, et al. (2014). A Multisite, Naturalistic, Observational Study of Transcranial Magnetic Stimulation (TMS) for Patients with Pharmacoresistant Major Depressive Disorder: Durability of Benefit Over a 1-Year Follow-Up Period. J Clin Psychiatry, 75(12):1394-1401. www.ncbi.nlm.nih.gov/pubmed/25271871

Janicak PG, et al. (2013). Transcranial Magnetic Stimulation (TMS) for Major Depression: A Multisite, Naturalistic, Observational Study of Quality of Life Outcome Measures in Clinical Practice. CNS Spectr, 18(6):322-332. www.ncbi.nlm.nih.gov/pubmed/23895940

Janicak PG, et al. (2010). Durability of Clinical Benefit with Transcranial Magnetic Stimulation (TMS) in the Treatment of Pharmacoresistant Major Depression: Assessment of Relapse During a 6-Month, Multisite, Open-Label Study. Brain Stimulation, 3(4):187-199. www.ncbi.nlm.nih.gov/pubmed/20965447

Janicak P, et al. (2008). Transcranial Magnetic Stimulation in the Treatment of Major Depressive Disorder: A Comprehensive Summary of Safety Experience from Acute Exposure, Extended Exposure, and During Reintroduction Treatment. J Clin Psychiatry, 69(2):222–232. www.ncbi.nlm.nih.gov/pubmed/18232722

Lisanby SH, et al. (2009). Daily Left Prefrontal Repetitive Transcranial Magnetic Stimulation in the Acute Treatment of Major Depression: Clinical Predictors of Outcome in a Multisite, Randomized Controlled Clinical Trial. Neuropsychopharmacology, 34(2):522-534. www.ncbi.nlm.nih.gov/pubmed/18704101

O’Reardon JP, et al. (2007). Efficacy and Safety of Transcranial Magnetic Stimulation in the Acute Treatment of Major Depression: A Multisite Randomized Controlled Trial. Biol Psychiatry, 62(11):1208-1216. www.ncbi.nlm.nih.gov/pubmed/17573044

Sackeim HA, et al. (2020). Clinical Outcomes in a Large Registry of Patients with Major Depressive Disorder Treated with Transcranial Magnetic Stimulation. J Affective Disorders, 277(12):65-74. https://pubmed.ncbi.nlm.nih.gov/32799106/

Simpson KN, et al. (2009). Cost-Effectiveness of Transcranial Magnetic Stimulation in the Treatment of Major Depression: A Health Economics Analysis. Adv Ther, 26(3):346-368. www.ncbi.nlm.nih.gov/pubmed/19330495

A National Institute of Mental Health (NIMH) sponsored clinical program using the NeuroStar system was conducted at four medical centers:

George MS, et al. (2010). Daily Left Prefrontal Transcranial Magnetic Stimulation Therapy for Major Depressive Disorder: A Sham-Controlled Randomized Trial. Arch Gen Psychiatry, 67(5):507–516. www.ncbi.nlm.nih.gov/pubmed/20439832